The Journal
Evidence-based research articles on peptide science. Written for researchers, biohackers, clinicians, and science-driven individuals who want depth over simplicity.
FDA's 503B GLP-1 Compounding Ban Reaches Its Final Hour — What Happens After the Comment Window Closes
The FDA's public comment period on permanently banning 503B compounding of semaglutide, tirzepatide, and liraglutide closed today. Here's what it means, why it matters, and what happens next — including the July 23–24 PCAC hearing on BPC-157 and TB-500.
Read article →The July 2026 FDA Hearing: BPC-157, TB-500, MOTS-c, and Six Other Peptides Head to PCAC — Here's What It Means and How to Participate
On July 23–24, the FDA's advisory committee votes on whether BPC-157, TB-500, MOTS-c, KPV, DSIP, Semax, and Epitalon should be added to the 503A compounding bulks list. Oral testimony registration closes June 30, 2026.
Read article →Europe's Peptide Reckoning: Raids, Regulations, Counterfeit Ozempic, and the Continent's Rapidly Shifting Enforcement Landscape
EMA's first-ever synthetic peptide guideline, Europol's 3,354 prosecutions, the UK's £45M seizure year, and counterfeit Mounjaro in Birmingham clinics. The full picture of Europe's transformed enforcement landscape.
Read article →Inside the Peptide Grey Market: China, Cartels, Crypto, and What's Not Being Tested
Chainalysis traced grey-market peptide vendors to former fentanyl cartel suppliers. The $100M shadow economy, the testing collapse, and what's actually in that vial.
Read article →Peptides in Mexico: Medical Tourism, Border Rules, and What the Research Landscape Actually Looks Like
Thousands of Americans cross into Mexico monthly for GLP-1s and peptide therapy. The full picture: COFEPRIS rules, pricing, top clinics, and the real risk of bringing peptides back across the border.
Read article →Triple Regulator (TIA-39-C20): GLP-1/GIP/Glucagon Triple Agonist Research Profile
TIA-39-C20 is a 39-amino acid triple GLP-1/GIP/glucagon receptor agonist with a C20 fatty diacid chain. Triple receptor activation adds resting energy expenditure via glucagon signaling on top of dual incretin effects. Phase 3 data shows up to 28.7% weight loss — the highest in controlled obesity trials. Full research profile and literature review.
Read article →Dual Regulator (DIA-39-C20): GLP-1/GIP Dual Incretin Agonist Research Profile
DIA-39-C20 is a 39-amino acid dual GIP/GLP-1 receptor agonist with a C20 fatty diacid chain. Synergistic dual incretin activation produces greater appetite suppression and fat oxidation than single agonism alone. Structurally analogous in class to tirzepatide. Full research profile and literature review.
Read article →Single Regulator (SIA-31-C18): GLP-1 Receptor Agonist Research Profile
SIA-31-C18 is a 31-amino acid GLP-1 receptor agonist featuring a C18 fatty diacid side chain for extended half-life. The first member of the Regulator Series — structurally analogous in class to semaglutide. Full research profile, mechanism, and published literature review.
Read article →FDA Peptide Reclassification 2026 — What the April Policy Shift Means for Researchers
The FDA's April 2026 reclassification of 12 research peptides — including BPC-157's removal from Category 2 — marks the most significant regulatory shift since the 2023 compounding crackdown. What changed, and what it means.
Read article →CagriSema (Cagrilintide + Semaglutide) Research Guide
CagriSema combines cagrilintide (amylin analogue) and semaglutide (GLP-1 agonist) into a once-weekly injection targeting two distinct satiety pathways. REDEFINE 1 Phase 3: 22.7% weight loss. FDA NDA filed December 2025, decision expected October 2026.
Read article →FDA GLP-1 503B Compounding Update — May 2026
On April 30, 2026, the FDA proposed permanently removing semaglutide, tirzepatide, and liraglutide from the 503B outsourcing facility bulks list. Comment period closes June 29, 2026. Here is exactly what changed and what it means for researchers.
Read article →Retatrutide (GLP-3 / Reta) -- The Triple Agonist Research Guide
Retatrutide -- called "Reta" or "GLP-3" in research communities -- is Eli Lilly's triple GLP-1/GIP/glucagon receptor agonist. TRIUMPH-4 Phase 3: 26-29% mean weight loss at 48-68 weeks, the highest ever recorded in a controlled obesity trial, with no plateau at trial end.
Read article →The KLOW Stack: GHK-Cu, KPV, BPC-157 and TB-500 Research Guide
The KLOW Stack adds KPV to the proven Glow trio — creating a four-peptide combination that addresses skin regeneration, tissue repair, vascularization, cellular mobilization, and anti-inflammatory signaling through four non-overlapping mechanisms simultaneously.
Read article →Chinese Peptides Explained: What the Research Actually Says
In January 2026, a NYT investigation made "Chinese peptides" a mainstream search term. This article addresses what the evidence actually shows about safety, sourcing, and responsible research.
Read article →VIP Peptide and the MCAS Research Protocol: A Guide
VIP is a 28-amino acid neuropeptide and endogenous immune modulator with targeted VPAC receptor biology. Its ability to reduce pro-inflammatory cytokines by up to 40% without broadly suppressing immune function makes it central to MCAS and CIRS research protocols.
Read article →What Are Research Peptides? A Beginner's Guide for 2026
A plain-language guide to what research peptides are, what the evidence shows, what the regulations are, and how to approach the information responsibly.
Read article →The Nootropic Peptide Stack: Cognitive Research Guide for 2026
Noopept, Semax, Selank, Pinealon, PE-22-28, and the Calm and Clarity blend — mechanisms, cognitive research applications, and principled stacking considerations across multiple brain pathways.
Read article →Peptides for Fat Loss: A Weight Management Research Guide
AOD-9604, GLP-1, GLP-1 Dual Agonist, GLP-3, Survodutide, and Cagrilintide — mechanisms, Phase 3 clinical data, and research protocol considerations across the full weight management peptide class.
Read article →CJC-1295 and Ipamorelin: The Growth Hormone Stack Research Guide
The most studied GHRH and GHRP combination in growth hormone research — receptor biology, why the pairing is synergistic rather than additive, and the full dosing protocol.
Read article →ARA-290 (Cibinetide) — Neuropathic Pain and Autoimmune Research Guide
ARA-290 is a non-hematopoietic EPO analogue with FDA Fast-Track designation for autoimmune small fiber neuropathy — activating the innate repair receptor (IRR) for neuroprotection and anti-inflammatory signaling without red blood cell stimulation.
Read article →The Glow Stack: GHK-Cu, BPC-157, and TB-500 for Skin and Hair Research
GHK-Cu activates approximately 31% of human tissue remodeling genes. Combined with BPC-157's angiogenesis signal and TB-500's anti-fibrotic and cellular mobilization effects, the stack addresses skin aging from three complementary angles.
Read article →Peptide Stacking Guide: How to Combine Peptides for Research
A complete guide to peptide stacking — mechanistic complementarity vs redundancy, the most researched combinations across all major categories, and timing and sequencing considerations.
Read article →P21 Peptide — CNTF-Derived Neurogenesis Research Guide
P21 is a CNTF-derived tetrapeptide that stimulates hippocampal neurogenesis and reduces tau phosphorylation without CNTF's adverse effects. Outperformed Cerebrolysin in comparative Alzheimer's animal studies. Blood-brain barrier penetrant.
Read article →The Khavinsky Longevity Protocol: Epithalon, Thymalin, and Pinealon
Professor Vladimir Khavinsky's bioregulator peptide protocol targeting three primary aging regulatory systems — the pineal gland, thymus, and brain cortex — with 40 years of research behind it.
Read article →SHLP2 and SHLP6 — The Expanding Mitochondrial-Derived Peptide Family
SHLP2 and SHLP6 complete the known mitochondria-encoded peptide family alongside MOTS-c and Humanin. SHLP2 adds cytoprotective and anabolic-sparing properties; SHLP6 shows a unique pro-apoptotic profile in cancer cells while protecting normal cells.
Read article →The Mito Stack: SS-31, MOTS-c, and NAD+ — A Mitochondrial Research Guide
SS-31 repairs the mitochondrial membrane, MOTS-c drives biogenesis, and NAD+ supplies the coenzyme currency both processes require. The most comprehensive mitochondrial research protocol currently available.
Read article →The Gut Healing Stack — Larazotide, KPV, and BPC-157 Research Protocol
The most comprehensive all-oral gut research protocol combining Larazotide for tight junction repair, KPV for mucosal anti-inflammation, and BPC-157 for tissue healing — three complementary mechanisms addressing all layers of gut dysfunction.
Read article →The Wolverine Stack: BPC-157 and TB-500 Research Guide
The most recognized peptide combination in tissue repair research. BPC-157 handles vascularization, TB-500 handles cellular mobilization — distinct mechanisms that together produce a broader repair signal than either alone.
Read article →Triptorelin and the HPG Axis Restart Protocol — Research Guide
Triptorelin is the most studied peptide for HPG axis testosterone restart after TRT or androgen suppression — a long-acting GnRH agonist whose initial LH/FSH flare response is exploited in single-dose (0.1mg) restart protocols.
Read article →The Longevity Master Stack — Epithalon, Thymalin, MOTS-c, and SS-31 Research Protocol
The most comprehensive anti-aging research protocol combining Epithalon (telomere-pineal axis), Thymalin (immune aging), MOTS-c (mitochondrial biogenesis), and SS-31 (membrane repair) — four distinct biological aging mechanisms targeted simultaneously.
Read article →GLP-1 vs GLP-1 Dual Agonist vs GLP-3: Mechanisms, Clinical Data, and Research Implications
The evolution from single GLP-1 receptor agonism to dual GIP/GLP-1 co-agonism and triple GLP-1/GIP/glucagon agonism represents one of the most significant progressions in metabolic medicine research of the past decade.
Read article →How to Reconstitute Peptides: A Step-by-Step Protocol Guide
Proper reconstitution is the foundation of accurate peptide research — errors in this step affect every downstream variable including dosing precision, stability, and sterility.
Read article →BPC-157: A Complete Research Guide
BPC-157 is one of the most extensively studied healing peptides in preclinical research, with over 500 published studies spanning tendon, muscle, gut, cardiovascular, and neurological applications.
Read article →The Mitochondrial-Derived Peptide (MDP) Family — MOTS-c, Humanin, SS-31, and the SHLP Series
A complete research guide to the full family of mitochondria-encoded peptides — MOTS-c, Humanin, SHLP2, SHLP6, and the role of SS-31 in mitochondrial membrane repair — the most comprehensive MDP reference available.
Read article →The Complete MCAS Peptide Research Protocol — VIP, LL-37, KPV, and TA-1
A comprehensive research guide to the four-peptide MCAS protocol — VIP for mast cell degranulation suppression, LL-37 for antimicrobial defense, KPV for mucosal anti-inflammation, and TA-1 for T-regulatory cell normalization.
Read article →The Gut-Brain Axis and Peptides — Larazotide, KPV, BPC-157, and VIP
How research peptides interact with the gut-brain axis — Larazotide for tight junction repair, KPV for mucosal anti-inflammation, BPC-157 for gut tissue healing, and VIP for bidirectional gut-brain neuroimmune signaling.
Read article →Senolytics and Peptides — FOXO4-DRI and the Science of Clearing Senescent Cells
FOXO4-DRI is the most researched peptide senolytic — selectively inducing apoptosis in senescent cells by blocking the FOXO4-p53 interaction. 2025 Nature Communications confirmed the mechanism at atomic resolution.
Read article →The Journal is an independent educational publication. All articles are written for research and educational purposes only and do not constitute medical advice. Always consult a qualified healthcare professional.